Evidence map›Paper›PMID 30705411›Full record

ArticleLeukemia2019

A novel method for detecting the cellular stemness state in normal and leukemic human hematopoietic cells can predict disease outcome and drug sensitivity.

Muhammad Yassin, Nasma Aqaqe, Abed Alkader Yassin, Peter van Galen, Eitan Kugler, Bradley E Bernstein, Maya Koren-Michowitz, Jonathan Canaani, Arnon Nagler, Eric R Lechman and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 3 countries.

Muhammad YassinDepartment of Pathology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel.
Nasma AqaqeDepartment of Pathology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel.
Abed Alkader YassinDepartment of Pathology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel.
Peter van GalenCenter for Cancer Research, Massachusetts General Hospital, Boston, MA, 02114, USA.
Eitan KuglerDepartment of Pediatric Hemato-Oncology, Schneider Children Medical Center, Petah Tikva, Israel.
Bradley E BernsteinCenter for Cancer Research, Massachusetts General Hospital, Boston, MA, 02114, USA.
Maya Koren-MichowitzHematology Division, Chaim Sheba Medical Center, Tel-Hashomer, Israel.ORCID http://orcid.org/0000-0002-7223-328X
Jonathan CanaaniHematology Division, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
Arnon NaglerHematology Division, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
Eric R LechmanPrincess Margaret Cancer Centre, University Health Network and Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
John E DickPrincess Margaret Cancer Centre, University Health Network and Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
Erno WienholdsPrincess Margaret Cancer Centre, University Health Network and Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
Shai IzraeliDepartment of Pediatric Hemato-Oncology, Schneider Children Medical Center, Petah Tikva, Israel.
Michael MilyavskyDepartment of Pathology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel. mmilyavsky@post.tau.ac.il.ORCID http://orcid.org/0000-0002-5083-0809
Tel Aviv University · ILSheba Medical Center · ILUniversity Health Network · CAMassachusetts General Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute leukemia is an aggressive blood malignancy with low survival rates. A high expression of stem-like programs in leukemias predicts poor prognosis and is assumed to act in an aberrant fashion in the phenotypically heterogeneous leukemia stem cell (LSC) population. A lack of suitable genome engineering tools that can isolate LSCs based on their stemness precludes their comprehensive examination and full characterization. We hypothesized that tagging endogenous stemness-regulatory regions could generate a genome reporter for the putative leukemia stemness-state. Our analysis revealed that the ERG  + 85 enhancer region can serve as a marker for stemness-state and a fluorescent lentiviral reporter was developed that can accurately recapitulate the endogenous activity. Using our novel reporter, we revealed cellular heterogeneity in several leukemia cell lines and patient-derived samples. Alterations in reporter activity were associated with transcriptomic and functional changes that were closely related to the hematopoietic stem cell (HSC) identity. Notably, the differentiation potential was skewed towards the erythro-megakaryocytic lineage. Moreover, an ERG  + 85

Indexed as

Enhancer Elements, GeneticHematopoietic Stem CellsHumansLeukemia, Myeloid, AcuteNeoplastic Stem CellsTranscriptional Regulator ERGERG protein, humanTranscriptional Regulator ERG

Identifiers

PMID30705411
OpenAlexW2913683730

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.